Privacy legislation should not amend current IRB regs, PhRMA testifies at House hearing on Condit bill.
Executive Summary
MEDICAL RECORDS PRIVACY LEGISLATION SHOULD NOT AMEND IRB REVIEW REGS, PhRMA maintained at a June 5 hearing of the House Government Reform/Government Management, Information & Technology Subcommittee. Glaxo Wellcome Worldwide Epidemiology Director Elizabeth Andrews testified on behalf of the Pharmaceutical Research & Manufacturers of America at the hearing, which was called by Subcommittee Chairman Rep. Horn (R-Calif.) to discuss privacy legislation introduced by Rep. Condit (D-Calif.) this session as HR 52.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth